CTAD 2022 View overview page

Next generation tau tracers: [18F]MK-6420 vs [18F]flortaucipir

Is amyloid load a valid surrogate endpoint for AD clinical trials?

Ongoing and future efforts in functional genomics in Alzheimer’s disease

What’s next for clinical trials in Alzheimer’s disease?

Precision medicine in Alzheimer’s treatment: genetics and co-pathologies

Astrocyte biomarkers associated with amyloid-β and tau pathologies

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Associations between predicted brain age and Alzheimer’s Disease biomarkers

Performance of plasma p-tau181 as a community-based screening tool for AD clinical trials

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

Nilotinib: a potential repurposed treatment for Alzheimer’s disease?

Can biomarkers help to predict brain age?

Lipidomics as a tool for dementia research

Personalized approach to dementia prevention and treatment

Can the APOEε4 genotype contribute to tau pathology progression?

The Phase III NILEAD trial: nilotinib as a novel treatment for AD